# Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

> **NCT01542736** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Medulloblastoma
- High Risk Supratentorial PNET
- Metastatic PNET

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Vincristine
- **RADIATION:** 24 Gy

## Key facts

- **NCT ID:** NCT01542736
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542736, "Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01542736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*